Harbin Medisan Pharmaceutical Balance Sheet Health
Financial Health criteria checks 3/6
Harbin Medisan Pharmaceutical has a total shareholder equity of CN¥2.1B and total debt of CN¥906.2M, which brings its debt-to-equity ratio to 42.2%. Its total assets and total liabilities are CN¥3.6B and CN¥1.4B respectively.
Key information
42.2%
Debt to equity ratio
CN¥906.17m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥840.63m |
| Equity | CN¥2.15b |
| Total liabilities | CN¥1.41b |
| Total assets | CN¥3.56b |
Recent financial health updates
Recent updates
Harbin Medisan Pharmaceutical Co., Ltd.'s (SZSE:002900) Shares Climb 25% But Its Business Is Yet to Catch Up
Nov 11
Harbin Medisan Pharmaceutical (SZSE:002900) Posted Weak Earnings But There Is More To Worry About
Sep 05Harbin Medisan Pharmaceutical (SZSE:002900) Will Pay A Larger Dividend Than Last Year At CN¥0.20
Jun 01Is Harbin Medisan Pharmaceutical (SZSE:002900) A Risky Investment?
May 23Harbin Medisan Pharmaceutical Co., Ltd.'s (SZSE:002900) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Mar 08Financial Position Analysis
Short Term Liabilities: 002900's short term assets (CN¥1.3B) exceed its short term liabilities (CN¥1.1B).
Long Term Liabilities: 002900's short term assets (CN¥1.3B) exceed its long term liabilities (CN¥337.6M).
Debt to Equity History and Analysis
Debt Level: 002900's net debt to equity ratio (3.1%) is considered satisfactory.
Reducing Debt: 002900's debt to equity ratio has increased from 11% to 42.2% over the past 5 years.
Debt Coverage: 002900's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if 002900's interest payments on its debt are well covered by EBIT.